The reiterated Buy rating and maintained $12 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Aravive's stock in the short term. This reaffirmation of confidence in the company's potential can lead to increased investor interest and a potential upward movement in the stock price.